The newly released report entitled “Global COVID-19 Therapeutics Market– By Trends, Industry Competition Analysis, Clinical Trial/Pipeline Analysis, Revenue and Forecast Till 2034.” of InsightAce Analytic Pvt. Ltd. features in-depth analysis and an extensive study on the market, exploring its significant factors.
According to the latest market intelligence report by InsightAce Analytic, the global COVID-19 Therapeutics Market is expected to grow at a 15.0% CAGR during the forecast period for 2025-2034.
Request For Free Sample Page:
https://www.insightaceanalytic.com/request-sample/1184
COVID-19, an infectious disease caused by the most recently identified strain of the coronavirus, has affected populations on a global scale. Treatment for the virus involves a range of therapeutic agents aimed at managing symptoms and improving patient outcomes. These include various drug classes such as corticosteroids, antivirals, monoclonal antibodies, and kinase inhibitors.
The growth of COVID-19 Therapeutics Market is primarily attributed increased prevalence of COVID-19 across globe. The market is further supported by rising awareness about coronavirus, and collective efforts by the pharmaceutical companies in the development of covid-19 therapeutic drugs.
Some of the key Players of COVID-19 Therapeutics market includes Atea Pharmaceuticals, Inc., CytoDyn, Celltrion, Eli Lilly and Company, NRX Pharmaceuticals, Shanghai Junshi Biosciences Co., Ltd., Veru Inc., Humanigen, Inc., Catalent, Inc., Cipla Limited, Molecular Partners AG, Merck, Novartis International AG, Regeneron Pharmaceuticals, Inc., Vir Biotechnology, Revive Therapeutics Ltd., Brii Biosciences Limited, GlaxoSmithKline plc, APEIRON Biologics AG, Bristol Myers Squibb, Janssen Pharmaceuticals, Trevena Inc, Ono Pharmaceutical Co., Ltd., Constant Therapeutics LLC, Amarin Corporation plc, FUJIFILM Toyama Chemical Co., Ltd., NeuroBo Pharmaceuticals, Inc., Innovation Pharmaceuticals Inc., Bellerophon Therapeutics, Sorrento Therapeutics, PhaseBio, Pfizer, Takeda, BioAegis Therapeutics, Roivant Sciences, A.I. Therapeutics, Inc., Celltex Therapeutics, Blade Therapeutics, Marinomed Biotech AG, Synairgen, SAb Biotherapeutics, Romark Laboratories, L.C., Kiniksa Pharmaceuticals, UNION therapeutics A/S, Fulcrum Therapeutics, and Other Prominent Players.
Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1184
Key Developments:
- In Nov 2021, Pfizer Inc. announced its investigational novel COVID-19 oral antiviral candidate, PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness.
- In Nov 2021, Merck and Ridgeback Biotherapeutics today announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization in the United Kingdom (U.K.) for molnupiravir (MK-4482, EIDD-2801), the first oral antiviral medicine authorized for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test
- In Oct 2021, Regeneron Pharmaceuticals, Inc. Announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for REGEN-COV® (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. REGEN-COV is a combination of two monoclonal antibodies that was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19, using Regeneron’s proprietary VelocImmune® and VelociSuite® technologies
- In June 2021, Roche announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and pediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)
- In May 2021, GlaxoSmithKline plc and Vir Biotechnology, Inc. announced the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for sotrovimab (previously VIR-7831), an investigational single-dose monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in adults and paediatric patients. Treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalisation or death in high-risk adult outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial
- In May 2021, The U.S. Food and Drug Administration approved an emergency use authorization to the antibody treatment developed by Vir Biotechnology (VIR.O) and GlaxoSmithKline (GSK.L) for treating mild-to-moderate COVID-19 in people aged 12 years and older. Sotrovimab belongs to a class of drugs called monoclonal antibodies, which mimic natural antibodies that the body generates to fight off infection
Geographically, North America is expected to account for the largest share in terms of R&D in the global covid-19 therapeutics market attributed to elevated government spending on the development of drugs, growing government initiatives for R&D of covid-19 vaccines, an increasing number of market players, and the implementation of favorable initiatives by the government in the US and Canada. However, The Asia Pacific region is expected to gain rapid growth in the target market owing to increasing efforts by the government to augment the drug production and increasing number of research and development activities. In Jun 2021, Eli Lilly and Company India has received approval from India’s drug regulator for emergency use of its antibody drugs combination, which is used for the treatment of mild to moderate COVID-19 patients. Company has received approval for monoclonal antibody drugs, bamlanivimab 700 mg and etesevimab 1400 mg. Both of these drugs are used together for the treatment of patients with mild to moderate COVID-19.
Get Specific Chapter/Information From The Report: @ https://www.insightaceanalytic.com/report/global-covid-19-therapeutics-market/1184
The Global COVID-19 therapeutic Market Segments
The Global COVID-19 therapeutic Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Infection Type
- HCoV-229E
- HCoV-OC43
- SARS-CoV
- New Haven CoV
- HKU1-CoV
- MERS-CoV
- Other Infection Types
The Global COVID-19 therapeutic Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Drug Class
- Monoclonal Antibodies
- Antiviral
- Anticoagulant
- Glucocorticoid
- Nitric oxide
- Other Drug Class
The Global COVID-19 therapeutic Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America COVID-19 Therapeutics market revenue (US$ Million) by Country, 2025 to 2034
- U.S.
- Canada
Europe COVID-19 Therapeutics market revenue (US$ Million) by Country, 2025 to 2034
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific COVID-19 Therapeutics market revenue (US$ Million) by Country, 2025 to 2034
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America COVID-19 Therapeutics market revenue (US$ Million) by Country, 2025 to 2034
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa COVID-19 Therapeutics market revenue (US$ Million) by Country, 2025 to 2034
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Get More Information :
https://www.insightaceanalytic.com/report/global-covid-19-therapeutics-market/1184
